Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 04, 2022

Tumor Mutational Burden and Efficacy of Pembrolizumab ± Chemotherapy as First-Line Therapy for Gastric Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Clin. Cancer Res 2022 Jun 03;[EPub Ahead of Print], KW Lee, E Van Cutsem, YJ Bang, CS Fuchs, I Kudaba, M Garrido, HC Chung, J Lee, HR Castro, J Chao, ZA Wainberg, ZA Cao, D Aurora-Garg, J Kobie, R Cristescu, P Bhagia, S Shah, J Tabernero, K Shitara, L Wyrwicz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading